USA TODAY - Crestor: It worked so well in a trial, the study was halted
CHICAGO — A trial of AstraZeneca’s heart drug Crestor was stopped early because the drug proved so effective that the study’s independent monitors felt it would be unethical to withhold treatment from half the volunteers, company officials said Monday.
“We’re excited,” says Lisa Nanfra of AstraZeneca.
The decision came late Sunday as leading doctors at an American College of Cardiology meeting here were advising against using the cholesterol-lowering drug ezetimibe, sold as Zetia and Vytorin, which failed to outperform a statin now sold as a generic.
Most Popular
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
Public Speaking - Owning “The Skills” Part II
The board’s ruling suggests that the study, called Jupiter, shows for the first time that Crestor prevents deaths, heart attacks, strokes, episodes of chest pain and other serious events. AstraZeneca did not release the findings.
Jupiter pitted Crestor against a placebo in more than 17,000 people who aren’t usually considered candidates for cholesterol-lowering statins, such as Crestor, because they don’t …
Read the full article with a Free Trial at MyWire.
